AbCellera Biologics (ABCL) Leases (2021 - 2025)
Historic Leases for AbCellera Biologics (ABCL) over the last 5 years, with Q3 2025 value amounting to $137.9 million.
- AbCellera Biologics' Leases rose 10186.77% to $137.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $137.9 million, marking a year-over-year increase of 10186.77%. This contributed to the annual value of $66.6 million for FY2024, which is 887.6% down from last year.
- Per AbCellera Biologics' latest filing, its Leases stood at $137.9 million for Q3 2025, which was up 10186.77% from $136.9 million recorded in Q2 2025.
- In the past 5 years, AbCellera Biologics' Leases ranged from a high of $137.9 million in Q3 2025 and a low of $6.6 million during Q1 2022
- Over the past 5 years, AbCellera Biologics' median Leases value was $68.5 million (recorded in 2024), while the average stood at $65.6 million.
- As far as peak fluctuations go, AbCellera Biologics' Leases skyrocketed by 63246.75% in 2023, and later crashed by 2616.97% in 2025.
- Over the past 5 years, AbCellera Biologics' Leases (Quarter) stood at $19.8 million in 2021, then soared by 308.27% to $80.8 million in 2022, then fell by 9.52% to $73.1 million in 2023, then fell by 8.88% to $66.6 million in 2024, then surged by 106.93% to $137.9 million in 2025.
- Its Leases stands at $137.9 million for Q3 2025, versus $136.9 million for Q2 2025 and $68.7 million for Q1 2025.